Induction and exacerbation of subacute cutaneous lupus erythematosus following mRNA-based or adenoviral vector-based SARS-CoV-2 vaccination

Clin Exp Dermatol. 2022 Jan;47(1):161-163. doi: 10.1111/ced.14858. Epub 2021 Sep 13.

Abstract

Evidence is accumulating that COVID-19 vaccines might induce or exacerbate autoimmune rheumatic diseases. The currently available COVID-19 vaccines include mRNA and recombinant adenoviral vector vaccines, both encoding SARS-CoV-2 spike protein production as the primary target for neutralizing antibodies. We report a case of subacute cutaneous lupus erythematosus (SCLE) following mRNA vaccination with the Pfizer mRNA vaccine BNT162b2, and summarize the current literature on CLE occurring after COVID-19 vaccination.

Publication types

  • Case Reports
  • Letter
  • Review

MeSH terms

  • Ad26COVS1 / adverse effects
  • Aged
  • BNT162 Vaccine / adverse effects*
  • COVID-19 / prevention & control*
  • ChAdOx1 nCoV-19 / adverse effects
  • Drug Eruptions / etiology*
  • Humans
  • Lupus Erythematosus, Cutaneous / chemically induced*
  • Male
  • SARS-CoV-2
  • Vaccination / adverse effects

Substances

  • Ad26COVS1
  • ChAdOx1 nCoV-19
  • BNT162 Vaccine